The chief executive of the pharmaceutical company Moderna has sounded alarm bells in the global market, saying that vaccines for the corona virus may not be effective against the omega kroon variant.
According to Reuters, Stephen Bansal, CEO of Moderna, told the Financial Times in an interview that existing vaccines for the corona virus were effective for the paradise delta variant, but not for the new strain of the virus.His remarks appeared to affect global crude oil, the dollar (Australian currency) and Japan's stock exchange. The statement also raised fears that the ineffectiveness of the vaccine could lead to the spread of the disease and increase the number of people in hospitals and prolong the epidemic.
He said that in order to talk more about this, it is necessary to look at the statistics first.
"However, all the scientists I've talked to are saying it's not going to be good."
The World Health Organization (WHO) says there is a "high risk" of developing a new type of corona virus called Omi Crone.
Due to this virus, the borders have started closing again and the economic recovery after two years has been overshadowed.
News of the new virus lowered the value of global stocks by nearly Ù¹ 2 trillion, while investors waited for more information about Biden's statement not to implement the lockdown had brought a stalemate in the markets. However, Moderna's chief comments have raised concerns among investors.
Authorities in the United States and other countries have issued orders for speeding up vaccinations and booster doses.
Among the countries that have imposed travel bans since Omekron came in is Hong Kong, which has barred foreigners from many countries.
These include Angola, Ethiopia, Nigeria and Zambia.
The first case of Omi Kroon variant was reported on November 24 and it has spread to more than 12 countries so far.
The World Health Organization (WHO) has called on countries to adopt a "risk-taking approach" to adjust international travel measures.
However, global sanctions have raised concerns about inequality in vaccine distribution.
